

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Infectious Diseases

61, 572-580

DOI: [10.1093/cid/civ324](https://doi.org/10.1093/cid/civ324)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Low Bone Mass in Behaviorally HIV-Infected Young Men on Antiretroviral Therapy: Adolescent Trials Network Study 021B. <i>Clinical Infectious Diseases</i> , 2012, 55, 461-468.	2.9	52
2	Bone loss in HIV. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 446-451.	1.2	56
3	<i>Editorial Commentary</i> : Unmasking the Bare Bones of HIV Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2015, 61, 581-583.	2.9	3
4	HIV epidemics among transgender populations: the importance of a trans-inclusive response. <i>Journal of the International AIDS Society</i> , 2016, 19, 21259.	1.2	1
5	Tenofovir and bone health. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 326-332.	1.5	105
6	Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1287-1294.	1.0	5
7	Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 287-294.	0.9	42
8	The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 80-86.	1.5	84
9	The protease inhibitors and HIV-associated bone loss. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 333-342.	1.5	36
10	Key Data from the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. <i>Antiviral Therapy</i> , 2016, 21, 75-89.	0.6	5
11	Protecting bone in long-term HIV positive patients receiving antiretrovirals. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 587-599.	2.0	4
12	Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. <i>Aids</i> , 2016, 30, 1973-1983.	1.0	721
13	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV</i> , 2016, 3, e521-e528.	2.1	66
14	HIV and Bone Complications: Understudied Populations and New Management Strategies. <i>Current HIV/AIDS Reports</i> , 2016, 13, 349-358.	1.1	21
15	Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. <i>Infectious Diseases and Therapy</i> , 2016, 5, 407-416.	1.8	15
16	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525.	1.9	40
17	Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 252-257.	0.9	25
18	Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. <i>Journal of the International AIDS Society</i> , 2016, 19, 20810.	1.2	67

#	ARTICLE	IF	CITATIONS
19	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016, 30, 915-920.	1.0	12
20	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	2.9	40
21	Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 265-273.	1.0	31
22	Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. <i>Current HIV/AIDS Reports</i> , 2016, 13, 116-124.	1.1	76
23	Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv221.	0.4	11
24	Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 195-209.	2.0	22
25	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 377-383.	0.3	11
26	Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 169-175.	0.8	2
27	Bone Loss in HIV Infection. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 52-67.	0.8	37
28	HIV preexposure prophylaxis for adolescents and young adults. <i>Current Opinion in Pediatrics</i> , 2017, 29, 399-406.	1.0	33
29	Sexually transmissible infection control programs for men who have sex with men – what will they look like in 2020?. <i>Sexual Health</i> , 2017, 14, 126.	0.4	4
30	Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 8-15.	0.3	0
31	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251.	1.0	47
32	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29
33	Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. <i>JAMA Pediatrics</i> , 2017, 171, 1063.	3.3	178
34	An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 21-29.	0.9	235
35	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 177-182.	0.9	25
36	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 377-383.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Bone health in HIV and hepatitis B or C infections. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 22-34.	1.2	32
38	Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2017, 64, 317-325.	2.9	54
39	Preexposure Prophylaxis in the United States: An Evolving HIV Prevention Opportunity. <i>Clinical Infectious Diseases</i> , 2017, 64, 150-151.	2.9	2
40	Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. <i>Journal of General Internal Medicine</i> , 2017, 32, 192-198.	1.3	88
41	Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature. <i>Antiviral Therapy</i> , 2017, 23, 379-382.	0.6	0
42	Recent advances in pre-exposure prophylaxis for HIV. <i>BMJ: British Medical Journal</i> , 2017, 359, j5011.	2.4	101
43	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	2.9	50
44	Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721.	2.9	48
45	HIV preexposure prophylaxis: An essential, safe and effective prevention tool for sexual health. <i>MÃ©decine Et Maladies Infectieuses</i> , 2018, 48, 318-326.	5.1	5
46	Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate. <i>Aids</i> , 2018, 32, 913-920.	1.0	26
47	Potential kidney toxicity from the antiviral drug tenofovir. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 102-112.	1.0	17
48	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. <i>Lancet, The</i> , 2018, 391, 839-849.	6.3	286
49	The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. <i>Journal of the International AIDS Society</i> , 2018, 21, e25096.	1.2	24
50	Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV. <i>Sexually Transmitted Infections</i> , 2018, 94, 163-168.	0.8	36
51	Advancing HIV Biomedical Prevention Research for At-Risk Adolescents. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 535-542.	0.9	7
52	Feasibility of vitamin D supplementation interventions to mitigate HIV pre-exposure prophylaxis-related bone mineral density loss: a cross-sectional survey. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2197-2204.	0.8	3
54	Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy275.	0.4	5
55	Qualitative Insights Into Adherence to HIV Pre-Exposure Prophylaxis (PrEP) Among Australian Gay and Bisexual Men. <i>AIDS Patient Care and STDs</i> , 2018, 32, 519-528.	1.1	10

#	ARTICLE	IF	CITATIONS
56	HIV Pre-Exposure Prophylaxis Medication for Adolescents and Young Adults: A Position Paper of the Society for Adolescent Health and Medicine. <i>Journal of Adolescent Health</i> , 2018, 63, 513-516.	1.2	30
57	Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced <i>Streptococcus</i> and increased <i>Erysipelotrichaceae</i> in rectal microbiota. <i>Scientific Reports</i> , 2018, 8, 15212.	1.6	24
59	Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. <i>PLoS ONE</i> , 2018, 13, e0195744.	1.1	6
60	Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults. <i>Current Pediatrics Reports</i> , 2018, 6, 114-122.	1.7	11
61	Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz338.	0.4	3
62	Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions. <i>Drugs</i> , 2019, 79, 1263-1276.	4.9	53
63	Antiretroviral Medications for the Prevention of HIV Infection. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 629-646.	1.9	6
64	Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. <i>Bioconjugate Chemistry</i> , 2019, 30, 2216-2227.	1.8	13
66	Primary Care Physician Attitudes and Intentions Toward the Use of HIV Pre-exposure Prophylaxis in Adolescents in One Metropolitan Region. <i>Journal of Adolescent Health</i> , 2019, 64, 581-588.	1.2	26
67	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.	0.5	8
68	Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 746-754.	0.5	3
69	Nonoccupational Postexposure Prophylaxis and Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention in Adolescents and Young Adults. <i>Advances in Pediatrics</i> , 2019, 66, 245-261.	0.5	3
70	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2214.	3.8	172
71	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2203.	3.8	219
72	Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 1339-1352.	1.2	7
73	Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24-week analysis (RIDAR). <i>Tj ETQq1 1.0.784314.orgBT /Ov</i>	1.0	14
74	BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. <i>HIV Medicine</i> , 2019, 20, s2-s80.	1.0	30
75	Effect of Vitamin D Supplementation on Bone Turnover Markers During HIV Pre-Exposure Prophylaxis Using Tenofovir Disoproxil Fumarate-Emtricitabine in Men Who Have Sex with Men. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 608-614.	0.5	4

#	ARTICLE	IF	CITATIONS
76	Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Caseâ€“Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 214-223.	0.9	8
77	Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?. <i>Current HIV/AIDS Reports</i> , 2019, 16, 141-150.	1.1	51
78	Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz463.	0.4	9
79	Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. <i>Osteoporosis International</i> , 2019, 30, 1125-1135.	1.3	23
80	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , The, 2019, 393, 143-155.	6.3	265
81	Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. <i>AIDS and Behavior</i> , 2019, 23, 1287-1296.	1.4	14
82	Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 123-128.	0.5	7
83	Viewpoint: Why you should provide HIV pre-exposure prophylaxis (PrEP) at your college health center. <i>Journal of American College Health</i> , 2020, 68, 119-123.	0.8	1
84	Bone Health in Patients With Liver Diseases. <i>Journal of Clinical Densitometry</i> , 2020, 23, 212-222.	0.5	27
85	Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. <i>Clinical Infectious Diseases</i> , 2020, 70, 687-691.	2.9	22
86	Emerging evidence from a systematic review of safety of preâ€“exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. <i>Journal of the International AIDS Society</i> , 2020, 23, e25426.	1.2	67
87	Preexposure Prophylaxis for Human Immunodeficiency Virus Infection for Men Who Have Sex with Men and Transgender Persons:. <i>Dermatologic Clinics</i> , 2020, 38, 233-238.	1.0	0
88	Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatmentâ€“Naïve Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 310-318.	0.9	127
89	Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa454.	0.4	3
90	<i>In Vitro</i> Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	8
91	Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV preâ€“exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25624.	1.2	7
92	Sexual orientationâ€“based disparities in bone health: Evidence of reduced bone mineral density and mineral content among sexual minority men but not women in multiple NHANES waves. <i>American Journal of Human Biology</i> , 2021, 33, e23534.	0.8	2
93	Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBEâ€“2). <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1332-1337.	1.3	8

#	ARTICLE	IF	CITATIONS
94	Implementing PrEP in the pharmacy. <i>Pharmacy Today</i> , 2020, 26, 39-53.	0.0	3
95	Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial. <i>Current HIV Research</i> , 2020, 18, 52-62.	0.2	4
96	Bone Mineral Density, Body Composition, and Mineral Homeostasis Over 24-Months in Urban South African Women With HIV Exposed to Antiretroviral Therapy. <i>JBMR Plus</i> , 2020, 4, e10343.	1.3	11
97	Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?. <i>Current HIV/AIDS Reports</i> , 2020, 17, 1-5.	1.1	9
98	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	9.5	74
99	Evaluation of the Microbiome in Men Taking Pre-exposure Prophylaxis for HIV Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2005-2013.	1.4	9
100	Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. <i>PLoS ONE</i> , 2021, 16, e0246272.	1.1	6
101	Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2021, 10, 165-186.	1.8	13
102	Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1367-1373.	1.0	11
103	Pre-Exposure Prophylaxis (PrEP) for HIV Infection in Cisgender and Transgender Women in the U.S.: A Narrative Review of the Literature. <i>Archives of Sexual Behavior</i> , 2021, 50, 1713-1728.	1.2	19
104	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2129-2136.	1.3	10
105	Inflammatory cytologic alterations in the oral epithelium associated with HIV pre-exposure prophylaxis: a preliminary study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, 534-539.	0.2	2
106	Human Immunodeficiency Virus Pre-Exposure Prophylaxis: Use of Emtricitabine/Tenofovir Alafenamide. <i>Journal for Nurse Practitioners</i> , 2021, 17, 673-676.	0.4	1
107	The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV. <i>HIV Medicine</i> , 2021, 22, 816-823.	1.0	4
108	The combined effects of age and HIV on the anatomic distribution of cortical and cancellous bone in the femoral neck among men and women. <i>Aids</i> , 2021, Publish Ahead of Print, 2513-2522.	1.0	2
109	Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. <i>Aids</i> , 2021, 35, 2481-2487.	1.0	8
110	Case 27-2021: A 16-Year-Old Boy Seeking Human Immunodeficiency Virus Prophylaxis. <i>New England Journal of Medicine</i> , 2021, 385, 1034-1041.	13.9	0
111	Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 867-871.	1.0	14

#	ARTICLE	IF	CITATIONS
112	The Effect of Tenofovir Disoproxil Fumarate on Bone Mineral Density: A Systematic Review and Meta-Analysis. <i>Antiviral Therapy</i> , 2020, 25, 21-32.	0.6	26
113	Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 500-506.	1.3	2
114	HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. <i>Nature Reviews Urology</i> , 2022, 19, 7-15.	1.9	6
116	Prevalence and risk factors for bone mineral density changes in antiretroviral therapy-naive human immunodeficiency virus-infected adults: a Chinese cohort study. <i>Chinese Medical Journal</i> , 2020, 133, 2940-2946.	0.9	4
118	CROI 2016: Complications of HIV Infection and Antiretroviral Therapy. <i>Topics in Antiviral Medicine</i> , 2016, 24, 38-46.	0.1	2
119	How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. <i>Journal of Virus Eradication</i> , 2018, 4, 215-224.	0.3	34
120	CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women. <i>BMJ Open</i> , 2022, 12, e052880.	0.8	18
121	Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac091.	0.4	0
122	Impact of Liver Cirrhosis on Bone Metabolism. <i>Digestive Disease Interventions</i> , 0, , .	0.3	0
123	Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). <i>AIDS and Behavior</i> , 0, , .	1.4	1
125	Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 199-204.	1.5	1
126	HIV Transmission Prevention. , 2021, , 30-50.		0